IFNB1 and neoplasm: IFN-β gene-modified MSCs via systemic administration have also been demonstrated to successfully migrate to the tumor environment and attenuate tumor growth in experimental animal models such as hepatocellular carcinoma, bronchioloalveolar carcinoma, and melanoma [14–16].